- Tourmaline Bio (TRML, Financial) to announce Phase 2 TRANQUILITY trial results on May 20, 2025.
- Pacibekitug is being evaluated for treating elevated high-sensitivity C-reactive protein and chronic kidney disease.
- Dr. Deepak L. Bhatt will join Tourmaline management in presenting the results.
Tourmaline Bio, Inc. (NASDAQ: TRML), a clinical biotechnology company, is set to reveal the topline results of its ongoing Phase 2 TRANQUILITY trial on May 20, 2025. The trial investigates the efficacy of pacibekitug, a promising treatment for patients suffering from elevated high-sensitivity C-reactive protein and chronic kidney disease. The announcement will be made via a conference call and webcast scheduled to begin at 8:30 a.m. ET.
Pacibekitug, the lead asset of Tourmaline Bio, is a long-acting, fully human, anti-IL-6 monoclonal antibody with a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. The drug, which has shown potential in earlier clinical trials, is currently being explored for atherosclerotic cardiovascular disease and thyroid eye disease, with future plans for expansion into more indications.
The presentation of the TRANQUILITY trial results will feature both the management of Tourmaline Bio and Dr. Deepak L. Bhatt, who is the Director of the Mount Sinai Fuster Heart Hospital and Chair of Tourmaline's Cardiovascular Scientific Advisory Board. Dr. Bhatt's extensive background in cardiovascular medicine contributes significantly to the advisory board’s insights and strategies.
Investors and interested parties can register to join the webcast via Tourmaline Bio's website, where a replay will also be made available for later access. Further information about the company and its ongoing research and development efforts can be found at Tourmaline Bio's website, and on their social media channels.
